Top analyst Phil Nadeau of Cowen is sharing key insights on Gilead Sciences, Inc. (NASDAQ:GILD) after organizing meetings between investors and senior management in Boston last week. Notably, the company’s COO, CFO the SCO were among a number of top management officials in attendance to field investors questions, especially surrounding the pending acquisition of Kite and its CAR-T platform Axi-Cel. Along with management’s enthusiasm on the potential for Axi-Cel to successfully penetrate the hematologic malignancies market of 200,000 patients in the U.S. and Europe by 2022, the company is additionally confident on its ability to expand Kite’s platform with other technologies moving forward.
About The Author
December 15, 2016
It looks like Nintendo’s making a miniature, inexpensive version of the original Nintendo 64 console
July 20, 2017
September 26, 2017